Connect with us at CPHI Japan to learn how our API expertise, combined with flexible CDMO services, can drive your next pharmaceutical project forward efficiently and effectively.
CPHI Japan 2026
Leveraging our 85+ years of API development and manufacturing expertise to offer customized solutions.
With over 350 products in our portfolio, we’re the leading international supplier of APIs.
Connect with us at CPHI Japan to learn how our API expertise, combined with flexible CDMO services, can drive your next pharmaceutical project forward efficiently and effectively.
Since our founding in 1935, TAPI has been at the forefront of advancing health through innovation and dedication. Today we continue to build on this strong legacy, driving progress in the pharmaceutical industry. Our commitment to health is unwavering, from developing high-quality generics to pioneering cutting edge solutions.
TAPI EHS&S Awards 2025: Celebrating the People Driving Safer, Smarter, More Sustainable Progress
Joint Interview: TAPI and Antheia on Partnership, Progress, and the Future of Pharma
Accelerating Peptide Innovation Through Science, Agility, and Collaboration
TAPI and Antheia Announce Strategic Partnership to Advance Commercialization of Biosynthetic Pharmaceutical Ingredients
Transforming GLP-1 Manufacturing with PAT-Generated Data: A Smarter, Greener Approach
Sustainable by Design: How TAPI is Building a Greener Future in API Manufacturing
How Innovative Computational Tools and Automation Are Reshaping Solid Form Development
Driving Innovation in Green Chemistry: Redox Biocatalysis Allowing Full Stereocontrol
Connect with us at CPHI Japan to learn how our API expertise, combined with flexible CDMO services, can drive your next pharmaceutical project forward efficiently and effectively.
TAPI’s CDMO team will be at TIDES US at Kiosk K12 to connect on advanced development and manufacturing solutions for peptides and oligonucleotides.
Meet TAPI at OPRD NA in Toronto, where our CDMO team will be available to discuss advanced development and manufacturing solutions.
Our ESG commitment shapes how we develop, manufacture, and deliver active pharmaceutical ingredients (APIs) and CDMO services, with a long-term view toward shared value and global well-being.
We are committed to minimizing our environmental footprint by integrating eco-conscious practices into our production and supply chain. From investing in energy-efficient technologies to reducing water usage and chemical waste, we actively pursue greener processes without compromising quality or compliance.
We maintain rigorous compliance standards, transparent reporting, and ethical business practices across our global operations. From quality control to cybersecurity, our governance framework ensures accountability and risk management at every level.
People are at the heart of everything we do, and we collaborate with our partners and communities to promote health, education, and opportunity. Ethical labor practices, ongoing workforce development, and a commitment to health equity are key pillars of our social impact strategy.
